Pneumococcal disease: cases caused by serotypes covered by Prevenar 13 vaccine
Updated 1 May 2026
Applies to England
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/pneumococcal-disease-cases-caused-by-serotypes-covered-by-pcv13/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine
The number of invasive pneumococcal disease (IPD) cases due to any of the 13 serotypes in Prevenar13™ was the lowest during the 2020 to 2021 epidemiological year due to the COVID-19 pandemic and its associated restrictions.
To date, the cumulative weekly number of cases among individuals aged under 2 years was higher than the previous epidemiological year (2024 to 2025) but lower than the 3 preceding epidemiological years (2021/2022 to 2023/2024).
The cumulative weekly number of cases to date among individuals aged 2 to 4 years was lower than in any year since the 2017 to 2018 epidemiological year, apart from the 2020 to 2021 epidemiological year.
The cumulative weekly number of cases to date among individuals aged 5 years and above was lower compared to the previous epidemiological year (2024 to 2025).
In PCV13 less than 2 years
Figure 1. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes in Prevenar13™: children aged under 2 years in England by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes, 254, 171 and 22 cases were reported in 2006 to 2007, 2009 to 2010 and 2013 to 2014 epidemiological years, respectively.
In PCV13 2 to 4 years
Figure 2. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes in Prevenar13™: children aged 2 to 4 years in England by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes, 128, 112 and 10 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
In PCV13 5 to 64 years
Figure 3. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes in Prevenar13™: persons aged 5 to 64 years in England by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes 1,248, 1,247 and 403 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
In PCV13 over 65 years
Figure 4. Cumulative weekly number of reports of invasive pneumococcal disease due to any of the serotypes in Prevenar13™: persons aged 65 and over England by epidemiological year July to June (2017/2018 to 2025/2026 to date)
For comparison purposes 1,275, 1,017 and 367 cases were reported in 2006/2007, 2009/2010 and 2013/2014 epidemiological years, respectively.
The graphs are based on week of isolation so numbers for the most recent weeks may not be complete. Numbers of reported cases shown in the graphs are not adjusted to account for any change that may have occurred over time and between age groups in the proportion of all IPD cases that are serotyped.
The 7-valent pneumococcal conjugate vaccine (Prevenar 7™) was introduced into the childhood immunisation schedule on 4 September 2006.
The 13-valent pneumococcal conjugate vaccine (Prevenar 13™) was introduced into the childhood immunisation schedule on 1 April 2010.
The vaccine schedule for this vaccine changed for infants born on or after January 2020 (with doses given at 12 weeks and 1 year of age (1+1) instead of 8 weeks, 16 weeks and 1 year of age (2+1)), which corresponds with week 0 above.
Source: Immunisation and Vaccine Preventable Diseases Division, UKHSA (formerly Public Health England).